278 Preclinical development of LYL119, a ROR1-targeted CAR T-cell product incorporating four novel T-cell reprogramming technologies to overcome barriers to effective cell therapy for solid tumors

類似資料

• Engineering potent chimeric antigen receptor T cells by programming signaling during T-cell activation
  著者:: Aileen W. Li, 等
  出版事項: (2024-09-01)
• 50 números de LyL
  著者:: Javier González Riffo
  出版事項: (2024-10-01)
• Characterization of a pediatric T-cell acute lymphoblastic leukemia patient with simultaneous LYL1 and LMO2 rearrangements
  著者:: Irene Homminga, 等
  出版事項: (2012-02-01)
• Functional circuits of LYL1 controlled by supraphysiological androgen in prostate cancer cells to regulate cell senescence
  著者:: Mehdi Heidari Horestani, 等
  出版事項: (2024-12-01)
• 754 Phase 1 trial of LYL797, a ROR1-targeted CAR T-cell therapy enhanced with genetic and epigenetic reprogramming, in advanced triple-negative breast cancer (TNBC) and non-small cell lung cancer (NSCLC)
  著者:: Haven Garber, 等
  出版事項: (2023-11-01)